Cargando…

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex

The dorsal vagal complex (DVC) in the hindbrain, composed of the area postrema, nucleus of the solitary tract, and dorsal motor nucleus of the vagus, plays a critical role in modulating satiety. The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ludwig, Mette Q., Todorov, Petar V., Egerod, Kristoffer L., Olson, David P., Pers, Tune H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Diabetes Symposium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576419/ https://www.ncbi.nlm.nih.gov/pubmed/34176785 http://dx.doi.org/10.2337/dbi21-0003

Ejemplares similares

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
por: Fukuda, Makoto
Publicado: (2021)

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders
por: Samms, Ricardo J., et al.
Publicado: (2021)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors
por: Keller, Bailey N., et al.
Publicado: (2022)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

Regulation of food intake by astrocytes in the brainstem dorsal vagal complex
por: MacDonald, Alastair J., et al.
Publicado: (2019)

Glial Modulation of Energy Balance: The Dorsal Vagal Complex Is No Exception
por: Troadec, Jean-Denis, et al.
Publicado: (2022)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Action of Administered Ciliary Neurotrophic Factor on the Mouse Dorsal Vagal Complex
por: Senzacqua, Martina, et al.
Publicado: (2016)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
por: Ahrén, Bo
Publicado: (2023)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Synaptic Inputs to the Mouse Dorsal Vagal Complex and Its Resident Preproglucagon Neurons
por: Holt, Marie K., et al.
Publicado: (2019)

Defining Heterogeneity Among Women With Gestational Diabetes Mellitus
por: Powe, Camille E., et al.
Publicado: (2020)

Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
por: Dennis, John M.
Publicado: (2020)

A Primary Role for α-Cells as Amino Acid Sensors
por: Dean, E. Danielle
Publicado: (2020)

The Local Paracrine Actions of the Pancreatic α-Cell
por: Rodriguez-Diaz, Rayner, et al.
Publicado: (2020)

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization
por: Whitaker, Gina M., et al.
Publicado: (2012)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
por: Morais, Tiago, et al.
Publicado: (2023)

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study
por: Kubota, Mitsunobu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ijqtf0r2nihkblbg0ttsfdlsno